IC‐P‐017: Trajectory of Age‐associated Structural Changes in Early‐onset Alzheimer's Disease, for the Alzheimer's Prevention Initiative

Adam Fleisher,Yakeel Quiroz,Kewei Chen,Laura Jakimovich,Madelyn Gutierrez,Jessica Langbaum,Auttawut Roontiva,Pradeep Thiyyagura,Xiaofen Liu,Wendy Lee,Napatkamon Ayutyanont,Mark Nishimura,Stephanie Parks,Sergio Alvarez,Claudia Munoz,Victoria Tirado,Margarita Giraldo,Ken Kosik,Pierre Tariot,Francisco Lopera
DOI: https://doi.org/10.1016/j.jalz.2012.05.2128
2012-01-01
Abstract:To characterize the trajectory of biomarker changes associated with the preclinical course of Alzheimer's disease (AD) and prepare for re-symptomatic AD treatment trials, we are conducting AD biomarker studies in members of the world's largest known autosomal dominant early-onset AD (EOAD) kindred. Here we characterize and compare the cross-sectional age-associated structural brain changes associated with early-onset AD in presenilin 1 (PS1) E280A mutation carriers and non-carriers from Antioquia, Colombia. Fifty individuals, 20-56 years of age, including 19 asymptomatic carriers, 20 asymptomatic non-carriers, and 11 carriers with mild cognitive impairment (MCI) or dementia underwent a battery of brain imaging, CSF, and cognitive tests. T1-weighted volumetric magnetic resonance images (MRIs) were acquired using a 1.5T scanner. SPM8 was used for voxel based morphometry analyses. FreeSurfer was used to compute hippocampal, ventricular, and whole brain volumes, normalized for individual variations in intracranial volume. Voxel-wise and volume of interest (VOI) regression analyses were performed evaluating associations with age and mutation carrier status, and used to compare slopes of age-associated change. Subgroup comparison was performed on younger (median split at age 35) pre-symptomatic carriers (n = 10) versus non-carriers (n = 10) using independent two sample t-test analysis, alpha = 0.05. PS1-E280A mutation carriers had significantly greater age-related reductions in regional gray matter than non-carriers, most prominently in the bilateral parietal temporal, medial temporal, anterior/posterior cingulate and precuneus cortex, as well as greater reductions in bilateral hippocampal and whole brain volumes, and greater increases in ventricular volumes. Asymptomatic carriers under the age of 35 had significantly less gray matter than the non-carriers bilaterally in the precuneus and lateral parietal cortex. Rates of age-associated change were similar between all VOIs, and began to diverge at ages 36-39 between carriers and non-carriers, driven by changes in symptomatic individuals. This study demonstrates age-related brain tissue loss in early-onset AD-causing mutation carriers and distinguishes them from the brain tissue loss associated with normal aging. While some of the brain changes are associated with the symptomatic stages of AD, characteristic gray matter reductions are apparent at least than 10 years before the estimated age at clinical onset.
What problem does this paper attempt to address?